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ABSTRACT
Patients with aplastic anemia who do not have suitably HLA-matched, related donors generally receive immuno-
suppressive treatment as first-line therapy and are considered for transplantation from an unrelated donor only if
they fail to respond to immunosuppressive treatment. In this setting, rates of transplantation-related morbidity
and mortality have been high. We conducted a prospective study to determine the minimal dose of total body
irradiation (TBI) sufficient to achieve sustained engraftment when it is used in combination with 3 cycles of
30 mg/kg of antithymocyte globulin (ATG) and 4 cycles of 50 mg/kg of cyclophosphamide (CY). We also wanted
to determine the tolerability and toxicity of the regimen. The starting dosage of TBI was 3 × 200 cGy given over
2 days following CY/ATG. The TBI dose was to be escalated in increments of 200 cGy if graft failure occurred in
the absence of prohibitive toxicity, and de-escalated for toxicity in the absence of graft failure. Twenty-one female
and 29 male patients aged 1.3 to 46.5 years (median age, 14.4 years) underwent transplantation at 14 medical cen-
ters. The time interval from diagnosis to transplantation was 2.8 to 264 months (median, 14.5 months). All
patients had been transfused multiple times and all had received 1 to 11 courses (median, 4 courses) of immuno-
suppressive treatment and other modalities of treatment. In 38 cases, the donors were HLA-A, -B and -DR phe-
notypically matched with the patients, and, in 12 cases, the donor phenotype differed from that of the recipient by
1 HLA antigen. Recipients of mismatched transplants were considered separately for TBI dose modification, and
this study is still ongoing. Seven patients did not tolerate ATG and were prepared with 6 × 200 cGy of TBI plus
120 mg/kg of CY. Of the HLA-matched recipients prepared with CY/ ATG/TBI, all 20 who received 3 × 200 or
2 × 200 cGy of TBI achieved engraftment, and 10 are alive. Of the 13 patients who received 1 × 200 cGy of TBI,
1 failed to engraft, and 8 are alive. Each of 10 patients who received an HLA-nonidentical transplant achieved
engraftment, and 3 of 6 who were given 3 × 200 cGy of TBI, and 4 of 4 who were given 2 × 200 cGy are alive. Pul-
monary toxicity occurred in 8 of 30 patients who were given 3 × 200 or 2 × 200 cGy of TBI concurrently with
ATG and CY at 200 mg/kg, and in 2 of 13 patients who received 1 × 200 cGy of TBI, a pattern that suggests a
decrease in toxicity with TBI dose de-escalation. Overall, the highest probability of survival (73%) was observed
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INTRODUCTION
Hematopoietic stem cell transplantation from an allo-
geneic donor provides curative therapy for patients with
severe aplastic anemia. However, only 25% to 30% of
patients have a suitably HLA-matched, related donor and
proceed to transplantation as first-line therapy [1-3].
Patients who do not have a suitably HLA-matched, related
donor generally receive immunosuppressive therapy as the
treatment of choice. This is a reasonable approach because
acute toxicity is moderate and response rates as high as 80%
have been reported with this therapy [4,5]. However, recur-
rence of aplasia is frequent, and 20% to 45% of patients
receiving immunosuppressive therapy have been reported to
develop a clonal hematopoietic disorder 5 to 7 years after
treatment [6,7]. Nevertheless, these patients are generally
considered for transplantation from an unrelated donor only
when they fail to respond to immunosuppressive treatment
(often after repeated courses). They usually do not undergo
transplantation at the time of the initial diagnosis because
the results of immunosuppressive therapy are good [4,5],
transplantation-related mortality with unrelated donor
transplants historically has been high, and probability of
survival has been low [8,9]. Causes of transplantation failure
include increased incidence of graft rejection, regimen-
related toxicity due to intensified conditioning regimens
aimed at preventing rejection, and high incidence of acute
graft-versus-host disease (GVHD) [8-10].
In a pilot study of 5 patients who received transplants from
unrelated donors, we used antithymocyte globulin (ATG) and
cyclophosphamide (CY) treatment, a regimen used for patients
who receive transplants from HLA-identical sibling donors
[11]. In transplantations using HLA-identical sibling donors,
this regimen allows for successful outcomes in more than 90%
of patients. However, we observed at least 1 immunologic graft
rejection and 2 graft failures in transplantations using unrelated
donors; only 1 patient is currently surviving [12]. At the same
time, previous reports by European groups and by the
National Marrow Donor Program (NMDP) suggest that high-
dose irradiation regimens, although effective in securing
engraftment, will further increase toxicity without increasing
the probability of survival [8,13,14].
Therefore, with support from the NMDP, we initiated a
collaborative, multicenter, prospective, phase I study
designed to deﬁne the minimum effective dose of total body
irradiation (TBI) in conditioning regimens for patients with
aplastic anemia, who, having failed to respond to immuno-
suppressive therapy, received transplants from unrelated
donors [3]. Here, we present results on the ﬁrst 50 patients
enrolled in this study, indicating that a TBI dose of 200 cGy
(in combination with ATG and CY) is sufﬁcient to achieve
engraftment of transplants from HLA-matched unrelated
donors. The minimum effective dose of TBI for patients
who receive grafts from HLA-nonidentical unrelated donors
remains to be determined.
PATIENTS AND METHODS
The objective of this study was to determine the mini-
mum effective dosage of TBI, in combination with ATG
and CY, necessary to achieve engraftment in patients with
severe aplastic anemia who received transplants from unre-
lated donors [3]. Patients included in the study were those
with aplastic anemia who had failed to respond to the best
available immunosuppressive treatment by 75 days after ini-
tiation of therapy, who did not have an HLA-identical fam-
ily member, and who were aged 55 years or younger if an
HLA-A, -B, -DR phenotypically matched unrelated donor
was identiﬁed, or 35 years or younger if an HLA-nonidentical
donor was identiﬁed.
Patients
The study population consisted of 50 patients who pre-
sented with severe aplastic anemia (excluding patients with
Fanconi anemia) and who received bone marrow transplants
between February 1994 and June 1999 at 1 of 14 centers in
the United States, Germany, or the United Kingdom.
Forty-ﬁve donors were recruited through the NMDP (and
were registered with the NMDP), and 5 through other reg-
istries. All patients were registered with the study coordina-
tor at the Fred Hutchinson Cancer Research Center in
Seattle for TBI dosage assignment. Patient and transplant
characteristics are summarized in Table 1. Patients were
aged between 1.3 and 46 years (median, 14 years). All had
been transfused with either red blood cells or platelet
preparations, or both, and all had received immunosup-
pressive therapy, growth factors, and other modalities of
treatment with 1 to 11 agents (median, 4). The protocol
required that patients had received at least 1 course of
conventional immunosuppressive therapy with either no
hematologic response or a response followed by recur-
rence of marrow aplasia. Following failure of immunosup-
pressive therapy, patients were eligible for this protocol
even if hematologic parameters did not satisfy the criteria
for severe aplastic anemia at the time of recurrence.
among patients who underwent transplantation within 1 year of diagnosis, compared with patients who under-
went transplantation after a longer period of disease. In addition, younger patients (aged ≤20 years) were more
likely to survive than older patients (aged >20 years). Thus, for patients with an HLA-matched, unrelated donor,
a TBI dose of 200 cGy (in combination with CY/ATG) was sufficient to allow for engraftment without inducing
prohibitive toxicity. As in previous studies, patient age and pretransplantation disease duration remain important
prognostic factors.
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Donor Selection, Marrow Collection, and Processing
The donors were 20 women and 28 men (sex informa-
tion was unavailable for 2 donors) who were unrelated to
the patients. They were aged between 18 and 54 years
(median, 37 years), and were selected on the basis of HLA
typing available at the time of enrollment into the study. In
38 cases, the donor was HLA-matched with the patient for
HLA-A, -B and -C as determined by serologic typing, and
in some cases, by additional high-resolution oligonu-
cleotide typing [15,16]. In 12 cases, the donor phenotype
differed from that of the recipient by 1 HLA antigen. The
2 patient groups were considered separately for TBI dosage
determination. Bone marrow donations were collected at
37 unique collection centers, each of which harvested mar-
row from 1 to 6 donors. Marrows were harvested according
to the policies of the NMDP and brought to the transplan-
tation center by a courier.
Transplantation Regimen
The protocol prescribed 4 doses of intravenous CY,
50 mg/kg per day on 4 consecutive days, and, evenly spaced
between these, 3 infusions of horse ATG (ATGAM;
Upjohn, Kalamazoo, MI) at doses of 30 mg/kg. CY and
ATG were followed by TBI at a starting dosage of 3 × 200 cGy
(2 doses on 1 day, and 1 on the next day), followed by the
infusion of donor marrow [3]. As described in the statistical
section, dependent upon toxicity and efﬁcacy, the TBI dose
was to be escalated or de-escalated in steps of 200 cGy in
sequential groups of patients. Any organ system toxicity of
grade IV (by the Bearman criteria) [17] that was thought to
be related to the conditioning regimen was considered a
prohibitive toxicity. In addition, stomatitis, cardiac, pul-
monary, or hepatic toxicity of grade III severity based on the
Bearman criteria [17] was considered unacceptable toxicity.
Patients who could not complete the ATG regimen, because
of either a prior anaphylactic reaction or a severe adverse
reaction to the initial dose of ATG (n = 7), alternatively
received CY at 60 mg/kg per day for 2 consecutive days
(if the ﬁrst CY dose of 50 mg/kg had been given [1 patient],
the second CY dose was 70 mg/kg), followed by TBI (200 cGy
twice a day for 3 consecutive days for a total of 1200 cGy),
followed by donor marrow infusion.
Engraftment
The day of engraftment was defined as the first of
3 consecutive days on which the neutrophil count exceeded
0.5 × 109/L [18]. Therefore, patients who did not have a
neutrophil count of >0.5 × 109/L for 3 consecutive days at
any time posttransplantation were considered to have pri-
mary graft failure. Patients who survived for at least 21 days
and achieved initial engraftment but subsequently were
found to have a severely hypocellular marrow or an
absolute neutrophil count of <0.5 × 109/L were considered
to have secondary graft failure. Patients who survived fewer
than 21 days were considered evaluable for engraftment
only if they had developed GVHD before death. Marrow
and peripheral blood cells were tested sequentially for
chimerism using Y chromosome–specific complementary
DNA probes in patients with a donor of opposite sex or
probes speciﬁc for polymorphic DNA sequences (eg, vari-
able number tandem repeats).
Graft-Versus-Host Disease Prophylaxis
For GVHD prophylaxis, patients received a regimen as
described [19,20], including methotrexate at doses of
10 mg/m2 on days 1, 3, 6, and 11 after the marrow infusion,
and cyclosporine (Sandimmune, Sandoz, Basel, Switzer-
land), starting on day –1 at a dosage of 5 mg/kg per day as a
continuous infusion, de-escalated to 3 mg/kg per day on
day 4, and switched to the oral form at 12 mg/kg per day in
2 divided doses once the patient was able to take oral med-
ications. Cyclosporine was continued daily, and it was given
at gradually reduced doses from day 50 through day 180.
Acute GVHD was graded based on findings in the skin,
liver, and intestinal tract according to the Glucksberg
criteria as recently modiﬁed [21,22]. Chronic GVHD was
assessed as limited (mild skin involvement only) or extensive,
as described previously [23].
Data Collection
Data were collected in forms designed specifically for
this study, in addition to the standardized forms provided by
the NMDP. Data collection included pretransplantation
information, peritransplantation events, and follow-up at
6- to 12-month intervals. The median length of follow-up
was 39 months (range, 12 to 76 months). Data were ana-
lyzed as of July 1, 2000.
Table 1. Characteristics of 50 Patients With Aplastic Anemia and Their
Bone Marrow Donors*
Number of
Characteristic Patients
Age, y
Mean (range) 14 (1.3-46)
≤20 y 29
>20 y 21
Sex (M/F) 29/21
Race/ethnicity
White 36
Hispanic 9
African American 3
Asian 2
Disease duration, mo
Mean (range) 14.5 (2.8-264)
Pretransplantation therapy
Transfusions 50
Immunosuppression 50
No. of courses of therapy, 4 (1-11)
mean (range)
Donor age, y
Mean (range) 37 (22-54)
Donor sex (M/F) 28/20*
Donor/recipient sex
F/F 14
F/M 6
M/M 21
M/F 7
Donor/recipient HLA compatibility
Phenotypically matched 38
1-antigen–mismatched 12
*Data was not available for 2 patients.
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Study Design
This study was designed to develop and evaluate condi-
tioning regimens for patients with severe aplastic anemia
who received marrow transplants from unrelated donors.
The goal was to achieve sustained engraftment without
inducing prohibitive toxicity. The probability of graft
failure (and possibly treatment-related toxicity) was
expected to be different between patients receiving fully
HLA-matched grafts and patients receiving partially HLA-
mismatched grafts, and dosage determination was pursued
separately for the 2 groups.
Patients were to be treated in groups of 6, with the ﬁrst
group receiving 3 × 200 cGy. If more than 1 patient was reg-
istered at a given time and endpoints of toxicity or efﬁcacy
were not yet evaluable in preceding patients, the actual num-
ber of patients in a dosage cohort could be greater than 6.
Possible dosages for subsequent patients were 4 × 200, 5 ×
200, 6 × 200, or alternatively, 2 × 200 or 1 × 200 cGy. Guide-
lines were as follows: if 2 or more patients suffered unaccept-
able toxicity at a given dose, the next lower dose would be
chosen as the ﬁnal dosage for testing. If 1 patient suffered
unacceptable toxicity, the next 6 patients would be treated at
the same dosage level. This dosage was to be considered the
final dosage if no further patients experienced prohibitive
toxicity and at least 11 of 12 achieved engraftment. If, how-
ever, 2 or more of the 12 patients had unacceptable toxicity,
the next lower dosage was to be the ﬁnal dosage for testing.
If no patients suffered unacceptable toxicity and at least
1 patient failed to engraft, the dosage was to be escalated to
the next higher level. If all patients achieved engraftment,
the next group of patients was to be treated at the same
dosage level. The ﬁnal dosage was to be the dosage at which
11 of 12 patients achieved engraftment and no more than 1 of
12 suffered prohibitive toxicity. The properties of this TBI
dosage determination method were evaluated by Monte
Carlo simulation using various assumptions for the probabil-
ities of prohibitive toxicity and engraftment failure. For the
scenarios evaluated, this design had a high probability of
choosing an acceptable dosage level. Survival probabilities
were estimated by the Kaplan-Meier method. Likelihood
ratio tests from proportion hazards regression models were
used to compare survival among groups of patients.
RESULTS
Identification of Donors
Thirty-eight patients received transplants from pheno-
typically HLA-matched unrelated donors and 12 from HLA
1-antigen–mismatched donors (Table 1). The median time
from initiation of the formal donor search to transplantation
was 4 months (range, 2 to 65 months). Donor age and sex
are given in Table 1.
Conditioning Regimen
The conditioning regimens given to patients, dependent
upon tolerability of ATG and toxicity and efficacy of the
TBI schedule, are summarized in Figure 1.
Outcome
Engraftment. Transplantation outcomes are summa-
rized in Table 2. Patients were followed for a median of
39 months (range, 12 to 76 months). The median follow-up
period for surviving patients was 32 months. Three patients
died before day 21, one from cardiac toxicity, one from
anoxic encephalopathy due to airway clot, and one from pul-
monary damage. Of the 47 patients evaluable for engraft-
ment (ie, those who survived ≥21 days), 1 patient who was
conditioned with a regimen containing the lowest TBI dose
used (200 cGy) and who received a graft from a fully
matched donor failed to achieve sustained engraftment. The
remaining 46 patients, who received transplants from either
Figure 1. Conditioning regimen given to 50 patients who underwent
transplantation. Of the 50 patients, 43 (33 with grafts from HLA-
matched donors and 10 with grafts from HLA-mismatched donors)
were conditioned with CY + ATG + TBI at the dosages shown. Seven
patients (5 who received HLA-matched grafts and 2 who received
HLA-mismatched grafts) were unable to receive ATG and were condi-
tioned with CY and TBI only.
Table 2. Outcome of 50 Patients With Aplastic Anemia Who Received Bone
Marrow Transplants From Unrelated Donors*
No. of Patients 
Affected/No. of 
Evaluable
Parameter Patients (%)
Follow-up, mo
All patients, mean (range) 34 (6-70)
Surviving patients, mean (range) 27 (6-70)
Early deaths 3/50 (6)
Sustained engraftment 46/47 (98)
GVHD
Acute, grades II-IV 28/46 (61)
Chronic 11/30 (37)
Survival 29/50 (58)
CY + ATG + TBI regimen
HLA-identical donor
3 × 200 cGy 4/8 (50)
2 × 200 cGy 6/12 (50)
1 × 200 cGy 8/13 (59)
HLA-nonidentical
3 × 200 cGy 3/6 (50)
2 × 200 cGy 4/4 (100)
CY + TBI (6 × 200 cGy) regimen
HLA-identical 4/5 (80)
HLA-nonidentical 0/2 (0)
*GVHD indicates graft-versus-host disease; CY, cyclophos-
phamide; ATG, antithymocyte globulin; TBI, total body irradiation.
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an HLA-matched or an HLA 1-antigen–mismatched donor,
achieved sustained engraftment. There was no apparent dif-
ference in the tempo of hematologic recovery between
patients who had received different dosages of TBI.
Toxicity. Major toxicities by conditioning regimen are
summarized in Table 3, and causes of death are listed in
Table 4. Clinically signiﬁcant toxicity occurred in 15 (30%)
of the 50 patients enrolled. There was no apparent differ-
ence between patients given HLA-matched and HLA-
mismatched transplants. Although the number of patients
per regimen was small, the lowest incidence of toxicity,
15%, was seen in patients conditioned with the lowest dose
of TBI, 200 cGy. The lung was the most frequently affected
organ, and the most striking ﬁnding was that of diffuse alve-
olar damage generally manifesting at about 3 weeks post-
transplantation. This type of toxicity at the low dosages of
TBI administered was unexpected, and the mechanism is
not clear. One of us (R.H.) reviewed the autopsy tissue that
was available in 7 cases, and found that the histology was
remarkable in that hyaline membranes were formed most
prominently in the terminal broncheoli. The kidney was the
site of the next highest incidence of toxicity. No severe gas-
trointestinal or bladder toxicity was observed.
Graft-Versus-Host Disease. Although grades II to IV
acute GVHD occurred in 61% of patients, an expected
incidence with transplants from unrelated donors, clinical
manifestations were often mild to moderate. However, 2
patients died with acute GVHD and infection, and
1 patient who received a transplant from an HLA-
DQ–mismatched donor and was treated for extended peri-
ods of time with various immunosuppressive agents for
persistent GVHD, died with a posttransplantation lympho-
proliferative disorder involving primarily the intestinal
tract. Chronic GVHD requiring therapy developed in 11
(37%) of 30 evaluable patients.
Survival. As of July 2000, 29 (58%) of 50 patients are
surviving. Survival by dosage level of conditioning is shown
in Table 2. For both recipients of HLA-matched and HLA-
mismatched transplants, there appeared to be a slight increase
in survival probability with progressively de-escalating TBI
doses, however, this trend was not significant. Survival of
patients who received HLA 1-antigen–mismatched trans-
plants was comparable to that of patients who received fully
matched transplants. The most signiﬁcant factor for long-
term survival was the duration of the interval from diagnosis
to transplantation (Figure 2). Among patients who under-
went transplantation within 1 year of diagnosis, 73% survived,
compared to 53% of patients who underwent transplanta-
tion at 1 to 3 years after diagnosis, and 39% of patients who
underwent transplantation more than 3 years after diagnosis
(P = .32). Also, younger patients (aged ≤20 years) had a
higher probability of survival than older patients (aged
>20 years; P = .06) (Figure 3). In fact, 8 (89%) of 9 patients
aged ≤20 years who underwent transplantation within 1 year
of diagnosis are surviving, compared with 58% of patients
aged ≤20 years who underwent transplantation more than
1 year after diagnosis, and 43% of patients aged >20 years at
the time of transplantation (P = .06). Finally, 4 of the
7 patients are currently surviving who could not complete
the regimen because of ATG toxicity and were conditioned
with lower dosages of CY and 6 × 200 cGy of TBI. 
DISCUSSION
This prospective trial confirms results from previous
retrospective analyses which showed that bone marrow
transplantation with grafts from unrelated volunteer donors
offers curative therapy for patients with aplastic anemia
[3,8,10,24-26]. The best outcome was observed in younger
patients and in those who underwent transplantation within
the shortest time period from diagnosis [3,27,28].
The 2-year 57% survival rate in the present trial was supe-
rior to the 37% survival rate observed in our recent retrospec-
tive analysis of outcome in patients undergoing transplantation
Table 3. Toxicity by Pretransplantation Conditioning Regimens* 
No. Patients
Conditioning regimen With Toxicity/Total (%) Pulmonary Renal Oral Mucosal Hepatic CNS
ATG/CY (4 × 50) plus
3 × 200 cGy TBI 6/14 (36) 3 4 2 0 0
2 × 200 cGy TBI 5/16 (31) 5 2 0 0 0
1 × 200 cGy TBI 2/13 (15) 2 1 0 1 0
CY (2 × 60) plus
6 × 200 cGy TBI 2/7 (29) 2 1 1 1 1
All patients 15/50 (30) 12 8 3 2 1
*Severity of grade IV in any organ system or ≥grade III for pulmonary, oral mucosal (stomatitis), or hepatic toxicity [17]. ATG indicates antithy-
mocyte globulin; CY, cyclophosphamide; TBI, total body irradiation; CNS, central nervous system. 
Table 4. Causes of Death in Patients With Aplastic Anemia Who Received
Bone Marrow Transplants From Unrelated Donors*
Cause of Death No. of Patients
Diffuse alveolar damage 6
Other respiratory failure 2
Systemic infections 3
Organ failure† 5
PTLD‡ 1
Acute GVHD and associated problems 2
Asphyxia due to aspiration 1
Complications from second transplantation 1
*PTLD indicates posttransplantation lymphoproliferative disorder;
GVHD, graft-versus-host disease.
† See Table 3
‡ After extensive treatment for acute GVHD.
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under the auspices of the NMDP [3] and in other earlier
reports [8,10,26]. This survival ﬁgure suggests that the primary
objective of the prospective study, reduction of regimen-related
toxicity and mortality without jeopardizing engraftment, was
met. In fact, engraftment was achieved with the lowest TBI
dosage reached by dosage de-escalation, 1 × 200 cGy for
patients receiving HLA-matched transplants. However,
although decreased TBI dosages were associated with a lower
incidence of severe organ toxicity, the impact on survival was
not as conclusive as was anticipated, and differences were not
signiﬁcant, probably due in part to the small number of patients
in each group. To substantiate this data, a Phase II study using a
TBI dose of 200 cGy is currently underway. Dosage de-escala-
tion for recipients of HLA-nonidentical transplants on this pro-
tocol is still in progress, and results to date suggest that this
strategy will be beneﬁcial for these patients as well.
Earlier trials showed evidence that patients with aplastic
anemia have a poor tolerance for high-dosage TBI [29], and
it was this notion that provided the rationale for the present
trial. Of 7 patients who did not tolerate ATG and were
given higher dosages of TBI (6 × 200 cGy) with lower
dosages of CY (2 × 60 mg/kg), 4 are surviving (4 of 5 given
HLA-identical transplants). This outcome appears to be in
contrast to data from earlier studies that showed a 10% sur-
vival rate among patients with aplastic anemia who were
conditioned with CY/TBI and received a transplant from an
HLA-identical sibling [29]. However, the numbers are too
small to draw any firm conclusions. Furthermore, there
were numerous additional differences in the regimens used
in the present study, compared with earlier studies.
The same caution must be applied to any comparison
of outcome in patients prepared with 6 × 200 cGy of TBI
and 2 × 60 mg/kg of CY compared with that in patients
given much lower dosages of TBI (1 to 3 × 200 cGy) but in
combination with higher dosages of CY (4 × 50 mg/kg)
and ATG. The observed toxicities could be related to
high-dosage CY or interactions between high-dosage CY
and TBI, or conceivably, between TBI and ATG. The lat-
ter appears unlikely because ATG is well tolerated with
TBI (plus CY at 2 × 60 mg/kg) in patients undergoing
transplantation for malignant disorders [30]. Another
explanation for the high incidence of organ toxicity, in par-
ticular, pulmonary damage in patients with aplastic anemia,
might be the presence of an unusual cytokine profile.
Patients with aplastic anemia express high levels of proin-
flammatory cytokines such as interferon-γ and tumor
necrosis factor (TNF)-α [31]. TNF-α levels have been
shown to correlate with transplantation-related toxicity
and transplantation outcome [32]. Further upregulation by
high-dosage conditioning might lead to irreversible toxic-
ity and mortality. Also, Dirksen et al. [33] recently
reported high levels of interleukin (IL)-10 in a subgroup of
patients with aplastic anemia, and others [34] have
observed a correlation between a posttransplantation rise
in plasma levels of IL-10 (presumably related to macro-
phage activation) and death from complications, in partic-
ular, acute respiratory failure. Ten of 11 deaths in that
study occurred in patients who received transplants from
unrelated or HLA-nonidentical donors. Further investiga-
tions into this question appear warranted.
The probability of developing GVHD has been related
to the intensity of the conditioning regimen, at least after
transplantation of grafts from HLA-identical sibling donors
[19]. The 61% incidence of grades II to IV acute GVHD
and the 37% incidence of chronic GVHD in the present
trial were lower than those generally reported after unre-
lated donor transplantations [15,35], and GVHD was a
major factor contributing to death in only 3 patients. Con-
ceivably, therefore, lowering the dosage of TBI was beneﬁ-
cial in attenuating the development of GVHD.
In many respects, the present results confirm previous
observations [3], although the lack of a signiﬁcant impact of
HLA disparity on transplantation outcome was surprising.
However, considering the small number of patients involved,
these results must be interpreted cautiously. Nevertheless, if
the reduced dosage of TBI alleviated tissue damage and
augmentation of proinflammatory cytokine levels as dis-
cussed above, then this reduction may have modiﬁed clinical
Figure 2. Survival by pretransplantation disease duration. The survival
rate was 73% with a pretransplantation disease duration of <1 year
( ), 53% for 1 to 3 years ( ), and 39% for >3 years ( )
(P = .32).
Figure 3. The impact of patient age at the time of transplantation on
survival rates. The 2-year survival rate for 29 patients who were ≤20 years
of age ( ) at the time of transplantation was 67%, compared to
43% for 21 patients who were >20 years of age ( ) at the time of
transplantation (P = .06).
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manifestations of allogeneic interactions even after trans-
plantation from HLA-mismatched donors. The lowest TBI
dosage used here was identical to that currently employed in
so-called nonmyeloablative conditioning regimens. These
regimens generally incorporate agents other than CY, eg,
ﬂudarabine, and are well tolerated regarding acute toxicity
[36-38]. Some of those regimens also avoid the use of
methotrexate, another agent known to have mucosal and
pulmonary toxicity. Although GVHD occurs in a substantial
proportion of patients treated in this way, the manifestations
are often only mild to moderate [38]. Although the current
trial is still enrolling patients, one approach in follow-up pro-
tocols for patients with aplastic anemia who are receiving
transplants from unrelated donors might be a substantial
dosage reduction of CY, or even replacement of CY by other
agents such as ﬂudarabine. In addition, such a trial might use
mycophenolate mofetil (rather than methotrexate) or mono-
clonal antibodies for GVHD prophylaxis.
In conclusion, the results from our study are encouraging
for patients with aplastic anemia who do not have a suitably
HLA-matched related donor. TBI dosage reduction was
effective in reducing transplantation-related toxicity without
jeopardizing engraftment. The data suggest that in some
patients (especially young patients), transplantation with
grafts from unrelated donors should be carried out early in
the disease course, possibly before the patient has been
exposed to repeat courses of immunosuppressive therapy.
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